Lupin ties up with Amman Pharma
New Delhi: Drug firm Lupin on Thursday said it has received $25 million (around Rs 205 crore) from AbbVie Inc for meeting a key development milestone for a product to treat hematological cancers. The company has achieved a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program that is partnered with AbbVie Inc towards treatment across a range of hematological cancers. The drug maker had earlier received $30 million from AbbVie for achievement of other milestones in the programme. "This achievement is further validation of our ability to successfully develop novel treatments for unmet needs. We look forward to continuing successful development of this important treatment for patients with difficult-to-treat cancers," said Nilesh Gupta, Managing Director, Lupin.
